Pharmacology of new agents for acute heart failure syndromes

American Journal of Cardiology

Volumn 96, Issue 6 SUPPL., 2005, Pages 68-73

  Gheorghiade, Mihai ^a   Teerlink, John R ^b   Mebazaa, Alexandre ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CALCIUM SENSITIZER; CARVEDILOL; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; FELODIPINE; ISOSORBIDE 5 NITRATE; ITRACONAZOLE; KETOCONAZOLE; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; NEUROHORMONE; OR 1855; OXYGEN; PHOSPHODIESTERASE III INHIBITOR; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; RAPAMYCIN; SODIUM; TACROLIMUS; TEZOSENTAN; TOLVAPTAN; TROPONIN C; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN ANTAGONIST; VASOPRESSIN RECEPTOR; VASOPRESSIN V2 RECEPTOR; WARFARIN;

ACUTE HEART FAILURE; BLOOD VESSEL PERMEABILITY; CALCIUM CELL LEVEL; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DRUG USE; HEART ARRHYTHMIA; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HEMODYNAMICS; HUMAN; ISCHEMIA; MYOFILAMENT; NONHUMAN; PATIENT; PRIORITY JOURNAL; REVIEW; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; STUNNED HEART MUSCLE; SYNDROME; URINE VOLUME; VASOCONSTRICTION; VASODILATATION;

EID: 25144451694     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.07.023     Document Type: Article

References (85)

1. M. Packer, W.S. Colucci, L. Fisher, B.M. Massie, J.R. Teerlink, J.B. Young, C.J. Garratt Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure results with levosimendan in the REVIVE-1 study [abstract] J Card Fail 9 2003 S61
2. A. Mebazaa, A. Cohen-Solal, F. Kleber, M. Nieminen, M. Packer, S. Pocock, P. Põder, T. Sarapohja, M. Kivikko Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure Program and abstracts of the 8th Annual Scientific Meeting of the Heart Failure Society of America 2004 September 12-15, 2004; Toronto, Ontario, Canada. Abstract 231
3. M.S. Nieminen, J. Akkila, G. Hasenfuss, F.X. Kleber, L.A. Lehtonen, V. Mitrovic, O. Nyquist, W.J. Remme Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J Am Coll Cardiol 36 2000 1903 1912
4. M.T. Slawsky, W.S. Colucci, S.S. Gottlieb, B.H. Greenberg, E. Haeusslein, J. Hare, S. Hutchins, C.V. Leier, T.H. LeJemtel, E. Loh Study Investigators Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure Circulation 102 2000 2222 2227
5. V.S. Moiseyev, P. Poder, N. Andrejevs, M.Y. Ruda, A.P. Golikov, L.B. Lazebnik, Z.D. Kobalava, L.A. Lehtonen, T. Laine, M.S. Nieminen, K.I. Lie Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction a randomized, placebo-controlled, double-blind study (RUSSLAN) Eur Heart J 23 2002 1422 1432
6. F. Follath, J.G. Cleland, H. Just, J.G. Papp, H. Scholz, K. Peuhkurinen, V.P. Harjola, V. Mitrovic, M. Abdalla, E.P. Sandell, L. Lehtonen Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) a randomised double-blind trial Lancet 360 2002 196 202
7. R.J. Solaro, H.M. Rarick Troponin and tropomyosin proteins that switch on and tune in the activity of cardiac myofilaments Circ Res 83 1998 471 480
8. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart Circ Res 77 1995 107 113
9. H. Haikala, E. Nissinen, E. Etemadzadeh, J. Levijoki, I.B. Linden Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation J Cardiovasc Pharmacol 25 1995 794 801
10. H. Haikala, P. Kaheinen, J. Levijoki, I.B. Linden The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan Cardiovasc Res 34 1997 536 546
11. i in guinea-pig isolated ventricular myocytes Eur J Pharmacol 339 1997 97 100
12. G. Hasenfuss, B. Pieske, M. Castell, B. Kretschmann, L.S. Maier, H. Just Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium Circulation 98 1998 2141 2147
13. P.M. Janssen, N. Datz, O. Zeitz, G. Hasenfuss Levosimendan improves diastolic and systolic function in failing human myocardium Eur J Pharmacol 404 2000 191 199
14. 2+ sensitizer levosimendan in human myocardium Am J Physiol Heart Circ Physiol 282 2002 H131 H137
15. S. Szilagyi, P. Pollesello, J. Levijoki, P. Kaheinen, H. Haikala, I. Edes, Z. Papp The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations, and phosphodiesterase enzymes of the guinea pig Eur J Pharmacol 486 2004 67 74
16. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C a molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study J Biol Chem 269 1994 28584 28590
17. H. Haikala, J. Kaivola, E. Nissinen, P. Wall, J. Levijoki, I.B. Linden Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan J Mol Cell Cardiol 27 1995 1859 1866
18. J. Levijoki, P. Pollesello, J. Kaivola, C. Tilgmann, T. Sorsa, A. Annila, I. Kilpelainen, H. Haikala Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan structure-response and binding analysis with analogs of levosimendan J Mol Cell Cardiol 32 2000 479 491
19. T. Sorsa, S. Heikkinen, M.B. Abbott, E. Abusamhadneh, T. Laakso, C. Tilgmann, R. Serimaa, A. Annila, P.R. Rosevear, T. Drakenberg, P. Pollesello, I. Kilpelainen Binding of levosimendan, a calcium sensitizer, to cardiac troponin C J Biol Chem 276 2001 9337 9343
20. T. Sorsa, P. Pollesello, P. Permi, T. Drakenberg, I. Kilpelainen Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides J Mol Cell Cardiol 35 2003 1055 1061
21. 2+-sensitization Eur J Pharmacol 486 2004 1 8
22. H. Haikala, I.B. Linden Mechanisms of action of calcium-sensitizing drugs J Cardiovasc Pharmacol 26 suppl 1 1995 S10 S19
23. P.S. Pagel, M.F. McGough, D.A. Hettrick, D. Lowe, J.P. Tessmer, I.N. Jamali, D.C. Warltier Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy J Cardiovasc Pharmacol 29 1997 563 573
24. H. Tachibana, H. Cheng, T. Ukai, A. Igawa, Z. Zhang, W. Little, C. Cheng Levosimendan improves left ventricular systolic and diastolic performance at rest and during exercise after heart failure Am J Physiol Heart Circ Physiol 288 2005 H914 H922
25. S. Sonntag, S. Sundberg, L.A. Lehtonen, F.X. Kleber The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia J Am Coll Cardiol 43 2004 2177 2182
26. G.P. Aurigemma, W.H. Gaasch Clinical practice diastolic heart failure N Engl J Med 351 2004 1097 1105
27. E. Kristof, G. Szigeti, Z. Papp, A. Bodi, A. Facsko, L. Kovacs, J.G. Papp, E.G. Kranias, I. Edes Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function Ann N Y Acad Sci 853 1998 316 319
28. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit J Mol Cell Cardiol 30 1998 1115 1128
29. G. Hasenfuss, B. Pieske, B. Kretschmann, C. Holubarsch, N.R. Alpert, H. Just Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics J Cardiovasc Pharmacol 26 suppl 1 1995 S45 S51
30. H. Ukkonen, M. Saraste, J. Akkila, J. Knuuti, M. Karanko, H. Iida, P. Lehikoinen, K. Nagren, L. Lehtonen, L.M. Voipio-Pulkki Myocardial efficiency during levosimendan infusion in congestive heart failure Clin Pharmacol Ther 68 2000 522 531
31. J. Lilleberg, M.S. Nieminen, J. Akkila, L. Heikkila, A. Kuitunen, L. Lehtonen, K. Verkkala, S. Mattila, M. Salmenpera Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow, and myocardial substrate utilization early after coronary artery bypass grafting Eur Heart J 19 1998 660 668
32. H. Ukkonen, M. Saraste, J. Akkila, M.J. Knuuti, P. Lehikoinen, K. Nagren, L. Lehtonen, L.M. Voipio-Pulkki Myocardial efficiency during calcium sensitization with levosimendan a noninvasive study with positron emission tomography and echocardiography in healthy volunteers Clin Pharmacol Ther 61 1997 596 607
33. J. Pataricza, J. Hohn, A. Petri, A. Balogh, J.G. Papp Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein J Pharm Pharmacol 52 2000 213 217
34. + channel in rat arterial myocytes Eur J Pharmacol 333 1997 249 259
35. P. Kaheinen, P. Pollesello, J. Levijoki, H. Haikala Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels J Cardiovasc Pharmacol 37 2001 367 374
36. P.S. Pagel, C.P. Harkin, D.A. Hettrick, D.C. Warltier Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs Anesthesiology 81 1994 974 987
37. C.P. Harkin, P.S. Pagel, J.P. Tessmer, D.C. Warltier Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs J Cardiovasc Pharmacol 26 1995 179 188
38. N. Gruhn, J.E. Nielsen-Kudsk, S. Theilgaard, L. Bang, S.P. Olesen, J. Aldershvile Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties J Cardiovasc Pharmacol 31 1998 741 749
39. B.J. De Witt, I.N. Ibrahim, E. Bayer, A.M. Fields, T.A. Richards, R.E. Banister, A.D. Kaye An analysis of responses to levosimendan in the pulmonary vascular bed of the cat Anesth Analg 94 2002 1427 1433
40. J. Pataricza, I. Krassoi, J. Hohn, A. Kun, J.G. Papp Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery Cardiovasc Drugs Ther 17 2003 115 121
41. A.D. Michaels, B. McKeown, M. Kostal, K.T. Vakharia, M.V. Jordan, I.L. Gerber, E. Foster, K. Chatterjee Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake Circulation 111 2005 1504 1509
42. E.F. Du Toit, C.A. Muller, J. McCarthy, L.H. Opie Levosimendan effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart J Pharmacol Exp Ther 290 1999 505 514
43. ATP channels Anesth Analg 90 2000 5 11
44. D.M. Kopustinskiene, P. Pollesello, N.E. Saris Potassium-specific effects of levosimendan on heart mitochondria Biochem Pharmacol 68 2004 807 812
45. ATP channel opener Eur J Pharmacol 428 2001 311 314
46. + channel in cardiac function and cardioprotection Biochim Biophys Acta 1606 2003 1 21
47. ATP channels role in cardioprotection Cardiovasc Res 55 2002 429 437
48. J. Marin-Garcia, M.J. Goldenthal Mitochondria play a critical role in cardioprotection J Card Fail 10 2004 55 66
49. A. Mebazaa, D. Barraud, S. Welschbillig Randomized clinical trials with levosimendan Am J Cardiol 96 suppl 6A 2005 74G 79G
50. M.N. Zairis, C. Apostolatos, F. Anastassiadis, N. Kouris, H. Grassos, M. Sifaki, D. Babalis, S. Foussas Comparison of the effect of levosimendan, or dobutamine or placebo in chronic low output decompensated heart failure Calcium Sensitizer or Inotrope or None in Low Output Heart Failure (CASINO) Study In Program and abstracts of the European Society of Cardiology, Heart Failure Update 2004; June 12-15 2004 Wroclaw, Poland. Abstract 273
51. J. Lilleberg, S. Antila, M. Karlsson, M.S. Nieminen, P.J. Pentkainen Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers Clin Pharmacol Ther 56 1994 554 563
52. E.P. Sandell, M. Hayha, S. Antila, P. Heikkinen, P. Ottoila, L.A. Lehtonen, P.J. Pentikainen Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure J Cardiovasc Pharmacol 26 suppl 1 1995 S57 S62
53. M. Kivikko, S. Antila, J. Eha, L. Lehtonen, P.J. Pentikainen Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure Int J Clin Pharmacol Ther 40 2002 465 471
54. M. Kivikko, S. Antila, J. Eha, L. Lehtonen, P.J. Pentikainen Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure J Clin Pharmacol 42 2002 43 51
55. Data on file 2004 Abbott Laboratories North Chicago, IL
56. S. Antila, H. Huuskonen, T. Nevalainen, H. Kanerva, P. Vanninen, L. Lehtonen Site dependent bioavailability and metabolism of levosimendan in dogs Eur J Pharm Sci 9 1999 85 91
57. S. Antila, M. Kivikko, L. Lehtonen, J. Eha, A. Heikkila, P. Pohjanjousi, P.J. Pentikainen Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan Br J Clin Pharmacol 57 2004 412 415
58. S. Antila, U. Pesonen, L. Lehtonen, P. Tapanainen, H. Nikkanen, K. Vaahtera, H. Scheinin Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators Eur J Pharm Sci 23 2004 213 222
59. S. Antila, J. Eha, M. Heinpalu, L. Lehtonen, I. Loogna, A. Mesikepp, U. Planken, E.P. Sandell Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril Eur J Clin Pharmacol 49 1996 451 458
60. S. Antila, A. Jarvinen, J. Akkila, T. Honkanen, M. Karlsson, L. Lehtonen Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol Arzneimittelforschung 47 1997 816 820
61. S. Antila, T. Honkanen, L. Lehtonen, P.J. Neuvonen The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan Int J Clin Pharmacol Ther 36 1998 446 449
62. S. Antila, A. Jarvinen, T. Honkanen, L. Lehtonen Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin Eur J Clin Pharmacol 56 2000 705 710
63. P. Poder, J. Eha, S. Antila, M. Heinpalu, U. Planken, I. Loogna, A. Mesikepp, J. Akkila, L. Lehtonen Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease Cardiovasc Drugs Ther 17 2003 451 458
64. S. Sundberg, L. Lehtonen Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects Eur J Clin Pharmacol 55 2000 793 799
65. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, T. Masaki A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 1988 411 415
66. J.R. Teerlink The development of new medical treatments for acute decompensated heart failure Heart Fail Monit 2 2002 129 137
67. M. Clozel, G.A. Gray, V. Breu, B.M. Löffler, R. Osterwalder The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo Biochem Biophys Res Commun 186 1992 867 873
68. J.R. Teerlink, V. Breu, U. Sprecher, M. Clozel, J.P. Clozel Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries Circ Res 74 1994 105 114
69. D. Aronson, A.J. Burger Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure role of endothelin PACE Pacing Clin Electrophysiol 26 2003 703 710
70. M. Clozel, H. Ramuz, J.P. Clozel, V. Breu, P. Hess, B.M. Loffler, P. Coassolo, S. Roux Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use J Pharmacol Exp Ther 290 1999 840 846
71. M. Clozel, V. Breu, G.A. Gray, B. Kalina, B.M. Löffler, K. Burri, J.M. Cassal, G. Hirth, M. Müller, W. Neidhart Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist J Pharmacol Exp Ther 270 1994 228 235
72. 2-receptor blockade with tolvaptan in patients with chronic heart failure results from a double-blind, randomized trial Circulation 107 2003 2690 2696
73. M. Gheorghiade, W.A. Gattis, C.M. O'Connor, K.F. Adams Jr, U. Elkayam, A. Barbagelata, J.K. Ghali, R.L. Benza, F.A. McGrew, M. Klapholz, J. Ouyang, C. Orlandi Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure a randomized controlled trial JAMA 291 2004 1963 1971
74. Y. Yamane Plasma ADH level in patients with chronic congestive heart failure Jpn Circ J 32 1968 745 759
75. V.L. Szatalowicz, P.E. Arnold, C. Chaimovitz, D. Bichet, T. Berl, R.W. Schrier Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure N Engl J Med 305 1981 263 266
76. S.R. Goldsmith, G.S. Francis, A.W. Cowley Jr, T.B. Levine, J.N. Cohn Increased plasma arginine vasopressin levels in patients with congestive heart failure J Am Coll Cardiol 1 1983 1385 1390
77. G.A. Riegger, G. Liebau, K. Kochsiek Antidiuretic hormone in congestive heart failure Am J Med 72 1982 49 52
78. J. Penit, M. Faure, S. Jard Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture Am J Physiol 244 1983 E72 E82
79. 1a vasopressin receptor J Biol Chem 269 1994 3304 3310
80. S. Nielsen, T.H. Kwon, B.M. Christensen, D. Promeneur, J. Frokiaer, D. Marples Physiology and pathophysiology of renal aquaporins J Am Soc Nephrol 10 1999 647 663
81. Y. Yamamura, S. Nakamura, S. Itoh, T. Hirano, T. Onogawa, T. Yamashita, Y. Yamada, K. Tsujimae, M. Aoyama, K. Kotosai OPC-41061, a highly potent human vasopressin V2-receptor antagonist pharmacological profile and aquaretic effect by single and multiple oral dosing in rats J Pharmacol Exp Ther 287 1998 860 867
82. Z. Wang, K. Sekar, C. Orlandi, S.L. Bramer Tolvaptan has no effect on steady state amiodarone concentrations [abstract] Clin Pharmacol Ther 73 2003 P44
83. S. Shoaf, S. Kumara, S. Mallikaarjun, C. Orlandi, S. Bramer Lack of effect of tolvaptan on pharmacokinetics (PK) and pharmacodynamics (PD) of warfarin [abstract] Clin Pharmacol Ther 73 2003 P45
84. M. Gheorghiade, L. De Luca, G.C. Fonarow, G. Filippatos, M. Metra, G.S. Francis Pathophysiologic targets in the early phase of acute heart failure syndromes Am J Cardiol 96 suppl 6A 2005 11G 17G
85. M. Gheorghiade, W. Gattis Stough, K.F. Adams Jr, A.S. Jaffe, V. Hasselblad, C.M. O'Connor The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF) Am J Cardiol 96 suppl 6A 2005 18G 25G